GlobalData on MSN4mon
Palvella secures FDA grant for Phase III microcystic LMs treatment trialPalvella initiated the SELVA trial of QTORIN rapamycin for microcystic LMs in the third quarter of 2024. This 24-week, single ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback